Trial Profile
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Alisertib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 03 Feb 2022 Status changed from discontinued to completed.
- 15 Jun 2021 Planned primary completion date changed from 31 May 2021 to 31 May 2022.
- 01 Oct 2020 Status changed from active, no longer recruiting to discontinued, as per results published in the Oncologist.